Eli Lilly & Co (LLY) Stock Price & Analysis
Eli Lilly & Co (LLY) rose 0.86% to USD 1,196.03 as of July 25, 2026 at 01:12 UTC, according to Nexqual real-time market data.
LLY last closed at USD 1,185.87; the session ranged USD 1,187.5–1,206.94 on volume of 1,591,064 shares. Market capitalization is —, with a 52-week range of USD 623.78–1,249.45 (NYQ). Source: Nexqual, July 25, 2026 at 01:12 UTC.
Key Statistics (as of July 25, 2026 at 01:12 UTC)
| Price | USD 1,196.03 |
|---|---|
| Change | ▲ 0.86% (up) |
| Previous Close | USD 1,185.87 |
| Open | USD 1,194.35 |
| Day Range | USD 1,187.5 – 1,206.94 |
| 52-Week Range | USD 623.78 – 1,249.45 |
| Volume | 1,591,064 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (LLY)
Nexqual's technical model rates LLY "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 01:12 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 55.2 (neutral) |
| vs SMA50 | Above (USD 1,129.42) |
| MACD | 13.32 (positive) |
Analyst Ratings (LLY)
Wall Street analysts rate LLY "Buy" based on 27 analysts, with a mean price target of USD 1,270.37 (range USD 850–1,600), per Nexqual as of July 25, 2026 at 01:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 27 |
| Mean Target | USD 1,270.37 |
| High Target | USD 1,600 |
| Low Target | USD 850 |
| Buy / Hold / Sell | 22 / 5 / 2 |
Earnings (LLY)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 6.66 |
| Revenue Estimate | $20.69B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 8.55 vs est 6.79 ▲ beat |
| 2025-12-31 | USD 7.54 vs est 6.91 ▲ beat |
| 2025-09-30 | USD 7.02 vs est 5.89 ▲ beat |
| 2025-06-30 | USD 6.31 vs est 5.59 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financials & Fundamentals (LLY)
| Total Revenue | $72.25B |
|---|---|
| Revenue Growth (YoY) | +55.50% |
| Gross Margin | +82.83% |
| Operating Margin | +49.39% |
| Profit Margin | +34.99% |
| ROE | +107.46% |
| Debt / Equity | 139.02 |
| Current Ratio | 1.5 |
| Total Cash | $5.28B |
| Total Debt | $43.37B |
| Free Cash Flow | $9.16B |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financial Health Score (LLY)
Nexqual rates Eli Lilly & Co's overall financial health "Strong" across five dimensions, as of July 25, 2026 at 01:12 UTC.
| Growth | Strong — Revenue +56% YoY (latest Q) |
|---|---|
| Profitability | Strong — Gross margin 83%, operating 49% |
| Balance Sheet | Mixed — $5.28B cash vs $43.4B debt |
| Cash Flow | Solid — FCF $9.16B, 13% margin |
| Efficiency | Strong — ROE 107%, ROA 20.7% |
Ownership (LLY)
| Insider Ownership | +0.15% |
|---|---|
| Institutional Ownership | +85.14% |
| Float | 889.32M |
| Short % of Float | +1.05% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Leadership (LLY)
Eli Lilly & Co is led by David A. Ricks (age 57), Chairman & CEO, per Nexqual as of July 25, 2026 at 01:12 UTC.
| Chairman & CEO | David A. Ricks (age 57) |
|---|---|
| Executive VP & CFO | Lucas E. Montarce (age 48) |
| Chief Scientific & Product Officer and President of Lilly Research Laboratories | Daniel M. Skovronsky (age 51) |
| Executive VP, President of Lilly Oncology & Head of Corporate Business Development | Jacob S. Van Naarden (age 40) |
| Director of Investor Relations | Michael Czapar |
Major Backers & Investors (LLY)
Notable institutional backers of Eli Lilly & Co include Lilly Endowment, Inc, PNC Financial Services Group, Inc., Capital Group, according to Nexqual as of July 25, 2026 at 01:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Lilly Endowment, Inc | 9.6% |
| PNC Financial Services Group, Inc. | 5.45% |
| Capital Group | 4.28% |
| FMR, LLC | 2.8% |
| Fidelity | 1.08% |
| GROWTH FUND OF AMERICA | 1.06% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.43% |
| BlackRock | 8.16% |
| State Street | 4.8% |
| Geode Capital | 2.14% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
From Eli Lilly & Co's Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Pursuant to laws and regulations that include the Federal Food, Drug, and Cosmetic Act (FDCA) and the Public Health Service Act (PHSA), the FDA exercises jurisdiction over all of our products and devices in the U.S. and administers requirements covering the testing, safety, effectiveness, manufacturing, quality control, distribution, labeling, marketing, promotion, advertising, dissemination of information, and post-marketing surveillance of those products and devices.
- Currently, these government prices generally apply beginning at nine years (for medicines approved under a New Drug Application) or thirteen years (for medicines approved under a Biologics License Application) following FDA approval or licensure for the molecule and are set at a price that generally represents a significant discount from existing list prices to wholesalers and direct purchasers.
Partnerships
- In August 2023, HHS selected Jardiance, which is part of our collaboration with Boehringer Ingelheim, as one of the first ten medicines subject to government-set prices effective in 2026.
- To supplement our internal efforts, we collaborate with others, including academic institutions and research-based pharmaceutical and biotechnology companies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | USD 62.09 | ▲ 2.19% |
| MRK | Merck & Company, Inc. | USD 131.07 | ▲ 2.82% |
| NVO | Novo Nordisk A/S | USD 48.77 | ▲ 1.2% |
| ABT | Abbott Laboratories | USD 103.06 | ▲ 2.48% |
| AVGO | Broadcom Inc. | USD 381.92 | ▼ 3.75% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:12 UTC. This page is informational and not investment advice.